MENA AI-Based Clinical Trials Solution Provider Market: Current Analysis and Forecast (2023-2030)

An AI-based clinical trials solution provider is a company or organization that offers technological solutions and services leveraging artificial intelligence (AI) to support various aspects of clinical trials in the healthcare and pharmaceutical industries. These providers utilize AI algorithms, machine learning, natural language processing, data analytics, and other advanced technologies to enhance the efficiency, accuracy, and effectiveness of clinical trial processes.

The MENA AI-Based Clinical Trials Solution Provider Market is expected to grow at a strong CAGR of 28.09% during the forecast period (2023-2030). With the increasing need for faster and more accurate clinical trials, AI-based solutions are in demand to streamline processes. Adding to this, continuous advancements in AI technologies like machine learning and natural language processing are enhancing the capabilities of clinical trial solutions. Moreover, rising chronic diseases and the need for personalized medicine solutions are driving pharmaceutical companies and research institutions to embrace AI technologies for more efficient and targeted clinical trials. This growing collaborations between academic institutions, pharmaceutical companies, and AI startups are driving innovation. For instance, on 20 September 2023, Merck partnered with BenevolentAI and Exscientia to drive accelerated drug discovery with a higher probability of success. Access to end-to-end AI platform capabilities to generate novel development candidates in oncology, neurology, and immunology.

Based on phase, the market is segmented into Early Phase 1, Phase 1, Phase 2, Phase 3, and Phase 4. Among them, the phase 1 category held the largest share of the market in 2022. This is mainly due to the growing need for personalized medicine and tailored healthcare solutions and the surge in demand for AI-based clinical trial solution providers which mainly focuses on Phase 1 trials. For instance, on October 23, 2023, UAE Ministry of Finance launched digital transformation initiatives using metaverse and AI solutions. Moreover, their ability to offer innovative AI tools that enhance the efficiency and accuracy of Phase 1 trials attracts pharmaceutical companies and research organizations, driving the growth of the sector in the region.

Based on therapeutic application, the market is segmented into oncology, cardiovascular diseases, neurological diseases, metabolic diseases, infectious diseases, respiratory diseases, and others. Among them, the oncology category held a dominant share of the market in 2022. This is mainly due to witnessing a surge in cancer incidence and prevalence. As per the National Institute of Health, in 2022, around 463,675 new cancer cases are estimated to be in Arab countries, corresponding to 2.4% of the global incidence. Moreover, the increasing innovative approaches to accelerate drug development and improve clinical trial efficiencies in the MENA region and the growth of AI adoption in oncology clinical trials.

Based on the end user, the market is categorized into pharmaceutical companies, academia, and others. Among these, the academia category is expected to grow with a significant CAGR during the forecast period (2023-2030). This is mainly due to the training of the next generation of data scientists, bioinformaticians, and healthcare professionals with expertise in AI and clinical research. By offering specialized courses, workshops, and research opportunities, academic institutions nurture a capacity pool equipped to drive AI innovation in clinical trials and contribute to scientific advancements that benefit patients and healthcare stakeholders across the region.

For a better understanding of the market adoption of the AI-Based Clinical Trials Solution Provider industry, the MENA market is analyzed based on its worldwide presence in countries such as UAE, Saudi Arabia, Egypt, Israel, and the Rest of the MENA. Israel held a dominant share of the market in 2022 due to the country's strong infrastructure, investment, skilled workforce, and strategic partnerships with global pharmaceutical companies have propelled the growth of AI solutions in clinical research. For instance, in August 2023, Israel company QuantHealth captured USD 15 million in series A funding to expand the reach of AI-driven trial design. Adding to this, Israeli companies are leveraging AI algorithms and machine learning techniques to optimize various aspects of clinical trials, including patient recruitment, data analysis, and predictive modeling. Furthermore, Israel's supportive regulatory framework and access to a diverse patient population make it an ideal testing ground for innovative clinical trial technologies. As a result, the adoption of AI-based solutions by Israeli clinical research organizations and pharmaceutical companies continues to accelerate, driving further advancements in the industry.

Some of the major players operating in the market include IQVIA Inc, Merck KGaA, Pfizer Inc., Saama, Renalytix, Florence Healthcare, Geneyx Genomex, Insilico Medicine, NVIDIA Corporation, AiCure.